| Jill Ortiz, RPH | |
|
768 Mountain Ranch Rd, San Andreas, CA 95249-9707 | |
| (209) 754-3521 | |
| (209) 754-2544 |
| Full Name | Jill Ortiz |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 768 Mountain Ranch Rd, San Andreas, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598882458 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RPH40969 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jill Ortiz, RPH 768 Mountain Ranch Rd, San Andreas, CA 95249-9707 Ph: () - | Jill Ortiz, RPH 768 Mountain Ranch Rd, San Andreas, CA 95249-9707 Ph: (209) 754-3521 |
News Archive
Merck, known as MSD outside the United States and Canada, today provided the following statement after the conclusion of the Peripheral and Central Nervous System Drugs Advisory Committee meeting of the U.S. Food and Drug Administration about suvorexant, Merck's investigational medicine to treat insomnia.
While squamous cell anal carcinomas are rare, representing only about 2% of digestive-system cancer diagnoses, these cancers, which are associated with the human papillomavirus (HPV), sometimes prove very difficult to treat, recurring or developing metastases following standard treatment.
An international team of researchers has shed light on the potential impact of new drugs for hepatitis C virus (HCV).
RegeneRx Biopharmaceuticals, Inc. today announced the results of its first non-clinical dry eye study using RGN-259, RegeneRx's ophthalmic, preservative-free eye drop for the treatment of Dry Eye Syndrome (DES). In the study, animals were treated with RGN-259, a vehicle control and a positive control, doxycycline.
› Verified 2 days ago